
	Revenue		Net income attributable to Amedisys, Inc			Net income attributable to Amedisys, Inc. common stockholders (1)
	Revenue		Net income attributable to Amedisys, Inc			Basic			Diluted
2011:
1st Quarter (2) (3)	$	360.0	$	15.3		$	0.54		$	0.53
2nd Quarter (2) (4)		368.9		21.6			0.76			0.75
3rd Quarter (2) (5) (6)		370.7		(423.7	)		(14.73	)		(14.73	)
4th Quarter (2) (3) (6)		370.7		4.3			0.15			0.15

	$	1,470.3	$	(382.5	)	$	(13.33	)	$	(13.33	)

2010:
1st Quarter	$	404.5	$	36.6		$	1.32		$	1.29
2nd Quarter (7) (8) (9)		413.9		32.2			1.15			1.13
3rd Quarter (7) (8) (9)		396.7		21.6			0.77			0.76
4th Quarter (8) (9)		388.7		22.2			0.79			0.77

	$	1,603.8	$	112.6		$	4.02		$	3.95

(1)	Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.

(2)

During each of the four quarters of 2011, we incurred certain costs associated with the realignment of our operations and legal expenses related to the United States Senate Committee on Finance inquiry and SEC investigation. Net of income taxes, these costs amounted to $2.0 million, $0.7 million, $1.6 million and $1.8 million for the three-month periods ended March 31, 2011, June 30, 2011, September 30, 2011 and December 31, 2011, respectively.

(3)

During the first and fourth quarters of 2011, we incurred costs associated with our exit activities. See Note 13 to the consolidated financial statements for further details. Net of income taxes, these costs amounted to $0.7 million and $3.1 million for the three-month periods ended March 31, 2011 and December 31, 2011, respectively.

(4)	Our results for the three month period ended June 30, 2011, included a CMS bonus payment of $2.9 million net of income taxes as the result of the pay for performance demonstration.

(5)	Our results for the three month period ended September 30, 2011, included a release of a valuation allowance related to specific deferred tax assets in the amount of $1.9 million, net of income taxes.

(6)

During the third quarter of 2011, we recognized an estimated non-cash goodwill and other intangibles impairment charge of $434.6 million, net of income taxes. During the fourth quarter of 2011, we finalized our interim test of impairment of goodwill and as a result, recognized an additional non-cash goodwill and other intangibles impairment charge in the amount of $3.8 million, net of income taxes.

(7)

Our results for the three month period ended June 30, 2010 and September 30, 2010, included a CMS bonus payment of $2.2 million net of income taxes as the result of the pay for performance demonstration and $2.2 million net of income taxes for the settlement of our Georgia indigent care liability, respectively.

(8)

During the second, third and fourth quarters of 2010, we incurred certain costs associated with the realignment of our operations and legal expenses related to the United States Senate Committee on Finance inquiry and SEC investigation. Net of income taxes, these costs amounted to $2.1 million, $1.8 million and $1.9 million for the three-month periods ended June 30, 2010, September 30, 2010 and December 31, 2010, respectively.

(9)

During the second, third and fourth quarters of 2010, we incurred costs associated with our exit activities. See Note 13 to the consolidated financial statements for further details. Net of income taxes, these costs amounted to $0.9 million, $4.2 million and $3.2 million for the three-month periods ended June 30, 2010, September 30, 2010 and December 31, 2010, respectively.